- Home
- NKTR vs AGEN Comparison
NKTR vs AGEN Comparison
Compare NKTR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- AGEN
- Stock Information
- Founded
- NKTR 1990
- AGEN 1994
- Country
- NKTR United States
- AGEN United States
- Employees
- NKTR N/A
- AGEN N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NKTR Health Care
- AGEN Health Care
- Exchange
- NKTR Nasdaq
- AGEN Nasdaq
- Market Cap
- NKTR 108.3M
- AGEN 87.7M
- IPO Year
- NKTR 1994
- AGEN 2000
- Fundamental
- Price
- NKTR $25.16
- AGEN $5.72
- Analyst Decision
- NKTR Strong Buy
- AGEN Buy
- Analyst Count
- NKTR 6
- AGEN 4
- Target Price
- NKTR $77.50
- AGEN $13.00
- AVG Volume (30 Days)
- NKTR 4.5M
- AGEN 1.3M
- Earning Date
- NKTR 08-07-2025
- AGEN 08-07-2025
- Dividend Yield
- NKTR N/A
- AGEN N/A
- EPS Growth
- NKTR N/A
- AGEN N/A
- EPS
- NKTR N/A
- AGEN N/A
- Revenue
- NKTR $87,248,000.00
- AGEN $99,524,000.00
- Revenue This Year
- NKTR N/A
- AGEN $12.69
- Revenue Next Year
- NKTR N/A
- AGEN N/A
- P/E Ratio
- NKTR N/A
- AGEN N/A
- Revenue Growth
- NKTR N/A
- AGEN N/A
- 52 Week Low
- NKTR $6.48
- AGEN $1.38
- 52 Week High
- NKTR $37.38
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- NKTR 69.18
- AGEN 64.51
- Support Level
- NKTR $24.07
- AGEN $4.34
- Resistance Level
- NKTR $26.59
- AGEN $5.22
- Average True Range (ATR)
- NKTR 3.62
- AGEN 0.43
- MACD
- NKTR 1.20
- AGEN -0.00
- Stochastic Oscillator
- NKTR 58.40
- AGEN 95.17
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).